Last monday, June 24th, Thomas Wood showed you a potential biotech breakout trade in Amarin Corp (AMRN). Today it’s up nearly 15% on boosted revenue guidance due to strong demand for its Vascepa chronic cardiovascular treatment. We’re looking for a break above it’s 1- year high of $23.34, and it’s not to late to buy before the breakout.
Recent Related Articles
Amid a Bullish Yet Choppy Market, Here’s What Investors Should Do Now
How Our Traders Learned to Stop Worrying and Love the Volatility
As the Rally Pushes Its Luck, the Smart Money Seeks “Defensive Growth”
Friday Outlook: Next Week’s Setup—and a Tax Trick for Portfolio Laggards
How to Beat the Casino Economy (Without Losing Your Shirt)
Friday Outlook: The Fed, Not the Trade Truce, Calls the Shots
The Bull Turns Three and Refuses to Act Its Age
Friday Outlook: The Economy Makes No Sense — But Smart Investors Can Still Win
Exploring the Future of Options Trading with AI